Chugai Seiyaku Kabushiki Kaisha

Yoshihisa Murata

Atsushi Kimbara

Yoshihito Ohtake

Takeo Harada

Naoki Okamoto

Susumu Komiyama

Yoshiyuki Ono

Hirotaka Kashiwagi

Kenichi Nomura

Eisaku Mizuguchi

Nobuyuki Hori

Kazutaka Tachibana

Shota Tanaka

Mizuki Okuyama

Rie Saito

Naoshi Horiba

Shuichi Ohtomo

Yasuhiro Ichida

Mitsuaki Ide

Provided is a low-molecular compound or a salt thereof, or a solvate thereof which has the ability to activate Nrf2. The present invention provides a compound represented by the formula (1) or a salt thereof, or a solvate thereof, wherein Xis CRor N, Xis CRor N, R, Rand Rare each independently selected from the group consisting of hydrogen, halogen and C-Calkoxy, X, Xand Xare each independently selected from the group consisting of CH, O, NH, S and C═O, Y is C-Caryl optionally having a substituent or 5- to 10-membered heteroaryl optionally having a substituent, and Z is C-Caryl optionally having a substituent, 5- to 10-membered heteroaryl optionally having a substituent or C-Calkyl optionally having a substituent.

Nitrogen-containing heterocyclic compound having NRF2 activation effect

The present invention provides a dihydropyridazine-3,5-dione derivative or a salt thereof, or a solvate of the compound or the salt, a pharmaceutical drug, a pharmaceutical composition, a sodium-dependent phosphate transporter inhibitor, and a preventive and/or therapeutic agent for hyperphosphatemia, secondary hyperparathyroidism, chronic renal failure, chronic kidney disease, and arteriosclerosis associated with vascular calcification comprising the compound as an active ingredient, and a method for prevention and/or treatment.

Dihydropyridazine-3,5-dione derivative and pharmaceuticals containing the same

Growing community of inventors

Shizuoka, Japan

Yoshihisa Murata